ADMA Biologics, Inc. (ADMA) stock analysis
ADMA · ADMA Biologics, Inc.
Latest recorded price: USD 13.47
Model-estimated fair value: USD 27.22. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Biotechnology
At $13.47, ADMA trades 50.5% below the model's base-case value of $27.22. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $20.40 in the conservative case and $35.42 in the optimistic case, with a valuation confidence score of 45/100. Fiscal 2025 figures: revenue growth 49.0%, free cash flow margin 5.5%, ROIC 27.6%. The model flags 1 risk signal for this company.
Similar companies in Healthcare
- Agios Pharmaceuticals, Inc. (AGIO)
- Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
- AnaptysBio, Inc. - Common Stock (ANAB)
- Arrowhead Pharmaceuticals, Inc. - Common Stock (ARWR)
- Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
- Axsome Therapeutics, Inc. - Common Stock (AXSM)
- BridgeBio Pharma, Inc. - Common Stock (BBIO)
- Beam Therapeutics Inc. - Common Stock (BEAM)